Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-09-25
2007-09-25
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C548S953000
Reexamination Certificate
active
10516422
ABSTRACT:
There is provided pharmaceutically-acceptable acid addition salts of compounds of formula I,whereinR1represents C1-2alkyl substituted by one or more fluoro substituents;R2represents C1-2alkyl; andn represents 0, 1 or 2, which salts are useful as prodrugs of competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.
REFERENCES:
patent: 4346078 (1982-08-01), Bajusz et al.
patent: 4792452 (1988-12-01), Howard et al.
patent: 5498724 (1996-03-01), Nystrom et al.
patent: 5559232 (1996-09-01), Ackermann et al.
patent: 5602253 (1997-02-01), Antonsson et al.
patent: 5659071 (1997-08-01), Nystrom et al.
patent: 5705487 (1998-01-01), Schacht et al.
patent: 5707966 (1998-01-01), Schacht et al.
patent: 5710130 (1998-01-01), Schacht et al.
patent: 5723444 (1998-03-01), Antonsson et al.
patent: 5744487 (1998-04-01), Ohshima et al.
patent: 5780631 (1998-07-01), Antonsson et al.
patent: 5783563 (1998-07-01), Antonsson et al.
patent: 5856307 (1999-01-01), Antonsson et al.
patent: 5939392 (1999-08-01), Antonsson et al.
patent: 5965692 (1999-10-01), Gustafsson et al.
patent: 6030972 (2000-02-01), Bohm et al.
patent: 6051568 (2000-04-01), Gustafsson et al.
patent: 6221898 (2001-04-01), Antonsson
patent: 6225287 (2001-05-01), Edvardsson et al.
patent: 6255301 (2001-07-01), Gustafsson et al.
patent: 6262028 (2001-07-01), Antonsson et al.
patent: 6265397 (2001-07-01), Karlsson et al.
patent: 6337346 (2002-01-01), Gustafsson et al.
patent: 6337394 (2002-01-01), Karlsson et al.
patent: 6433186 (2002-08-01), Inghardt et al.
patent: 6440937 (2002-08-01), Baucke et al.
patent: 6440939 (2002-08-01), Edvardsson et al.
patent: 6444817 (2002-09-01), Bohm et al.
patent: 6455671 (2002-09-01), Bohm et al.
patent: 6479078 (2002-11-01), Hedstrom et al.
patent: 6521253 (2003-02-01), Forsman et al.
patent: 6576245 (2003-06-01), Lundgren et al.
patent: 6576657 (2003-06-01), Karlsson et al.
patent: 6599894 (2003-07-01), Inghardt et al.
patent: 6617320 (2003-09-01), Gustafsson et al.
patent: 6660279 (2003-12-01), Lundgren et al.
patent: 6716834 (2004-04-01), Andersson et al.
patent: 6750243 (2004-06-01), Inghardt et al.
patent: 6838478 (2005-01-01), Gustafsson et al.
patent: 6875446 (2005-04-01), Forsman et al.
patent: 6888007 (2005-05-01), Edvardsson et al.
patent: 6921758 (2005-07-01), Gustafsson et al.
patent: 6984627 (2006-01-01), Antonsson et al.
patent: 6998136 (2006-02-01), Lundgren et al.
patent: 7056907 (2006-06-01), Inghardt et al.
patent: 7129233 (2006-10-01), Inghardt et al.
patent: 2004/0019033 (2004-01-01), Inghardt et al.
patent: 2004/0242492 (2004-12-01), Inghardt et al.
patent: 2004/0242536 (2004-12-01), Khoo et al.
patent: 2005/0171083 (2005-08-01), Magnusson et al.
patent: 2006/0014734 (2006-01-01), Alami et al.
patent: 0185390 (1991-10-01), None
patent: 0526877 (1993-02-01), None
patent: 0293881 (1993-03-01), None
patent: 0530167 (1993-03-01), None
patent: 0539059 (1993-04-01), None
patent: 0195212 (1993-11-01), None
patent: 0468231 (1994-09-01), None
patent: 0641779 (1995-03-01), None
patent: 0648780 (1995-04-01), None
patent: 0362002 (1995-07-01), None
patent: 0686642 (1995-12-01), None
patent: 0364344 (1998-05-01), None
patent: 0542525 (1998-07-01), None
patent: 0559046 (2001-07-01), None
patent: 0669317 (2002-09-01), None
patent: 0773955 (2003-04-01), None
patent: 0672658 (2003-09-01), None
patent: 57149217 (1982-09-01), None
patent: WO93/11152 (1993-06-01), None
patent: WO93/18060 (1993-09-01), None
patent: WO94/29269 (1994-12-01), None
patent: WO94/29336 (1994-12-01), None
patent: WO95/23609 (1995-09-01), None
patent: WO95/35309 (1995-12-01), None
patent: WO96/03374 (1996-02-01), None
patent: WO96/25426 (1996-08-01), None
patent: WO96/26717 (1996-09-01), None
patent: WO96/31504 (1996-10-01), None
patent: WO96/32110 (1996-10-01), None
patent: WO97/02284 (1997-01-01), None
patent: WO97/23499 (1997-07-01), None
patent: WO97/39770 (1997-10-01), None
patent: WO97/46577 (1997-12-01), None
patent: WO97/49404 (1997-12-01), None
patent: WO98/01422 (1998-01-01), None
patent: WO98/06740 (1998-02-01), None
patent: WO98/16252 (1998-04-01), None
patent: WO98/57932 (1998-12-01), None
patent: WO99/21586 (1999-05-01), None
patent: WO99/29305 (1999-06-01), None
patent: WO99/29664 (1999-06-01), None
patent: WO99/39698 (1999-08-01), None
patent: WO 00/12043 (2000-03-01), None
patent: WO 00/13671 (2000-03-01), None
patent: WO 00/13710 (2000-03-01), None
patent: WO 00/14110 (2000-03-01), None
patent: WO 00/35869 (2000-06-01), None
patent: WO 00/42059 (2000-07-01), None
patent: WO 01/02426 (2001-01-01), None
patent: WO 01/87879 (2001-11-01), None
patent: WO 02/14270 (2002-02-01), None
patent: WO 02/19990 (2002-03-01), None
patent: WO 0244145 (2002-06-01), None
patent: WO 03/000293 (2003-01-01), None
patent: WO 03/018551 (2003-03-01), None
patent: WO 03/101423 (2003-12-01), None
patent: WO 03/101424 (2003-12-01), None
Baveja et al. “Zero-order release hydrophilic matrix tablets of beta-adrenergic blockers” International Journal of Pharmaceutics 39:39-45 (1987).
Bonferoni et al. “On the employment of lambda-carrageenan in a matrix system. II. Lambda-Carrageenan and hydroxypropylmethylcellulose mixtures” J. Controlled Release 30:175-182 (1994).
Berge et al. “Pharmaceutical Salts” J. of Pharmaceutical Sciences 66(1): 1-19 (1977).
Ham-Yong Park et al. “Effect of pH on Drug Release From Polysaccharide Tablets” Drug Delivery 5:13-18 (1998).
Picker “The use of carrageenan in mixture with microcrystalline cellulose and its functionality for making tablets” European J Pharmaceutics and Biopharmaceutics 48(1):27-36 (1999).
Talukdar et al. “In vivo evaluation of xanthan gum as a potential excipient for oral controlled-release matrix tablet formulation” International Journal of Pharmaceutics 169(1):105-113 (1998).
CAS RN 159776-70-2 Dec. 1994.
CAS RN 192939-72-3 Aug. 1997.
CAS RN 30318-53-4 Nov. 2000.
Ahlqvist Matti
Bohlin Martin
Inghardt Tord
Lundblad Anita
Sigfridsson Carl-Gustaf
Anderson Rebecca
AstraZeneca AB
Barker Michael P.
Morgan & Lewis & Bockius, LLP
LandOfFree
Salts does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Salts, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Salts will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3759419